Word: successful
(lookup in dictionary)
(lookup stats)
Dates: during 1980-1989
Sort By: most recent first
(reverse)
...away those dress-for-success books. Forget the management mystique. The key to thriving in the corporate jungle is understanding dinosaurs. So say Albert Bernstein, a clinical psychologist in Portland, Ore., and Sydney Craft Rozen, a former English instructor at Clark College in Vancouver, Wash. In Dinosaur Brains (John Wiley; $18.95) they examine the prehistoric reptile that lurks inside every employee like an evolutionary time bomb. Beneath that fragile fabric of reason called human intelligence, they argue, beats a powerful engine of lizard logic that demands instant gratification and lives to dominate. While the dinosaurs are long gone, their brains...
...Japanese must also decide whether to turn an unsavory scandal into an opportunity to reform their money-greased political system. That may prove the biggest challenge. Takeshita fell victim to his success at mastering the sometimes seamy rules of the system. In common with other party leaders, Takeshita indirectly received shares of cut-rate stock in Recruit, an aggressive information and real estate conglomerate. In all, Takeshita received more than $1 million in campaign contributions, stocks and secret loans from the company. The money went not to a personal account but to fund campaigns and pay staff salaries...
...stressed-out 1970s, F. Hoffmann-La Roche reached the peak of good health. Thanks largely to Valium and its sister sedative, Librium, the Swiss-based Hoffmann-La Roche became the No. 1 maker of prescription pharmaceuticals and one of the most profitable companies on earth. But lulled by the success of Valium, whose U.S. patent expired four years ago, the company failed to keep pace in the '80s with such aggressive rivals as U.S.-based Merck and Swiss neighbors Sandoz and Ciba-Geigy. Symbolic of Hoffmann-La Roche's backward ways was the firm's thinly held stock, the most...
Around the world, drug companies are teaming up in search of success. Britain's Beecham Group, purveyor of Tums antacid and Brylcreem hair lotion, last month merged with Philadelphia's SmithKline Beckman, developer of the antiulcer drug Tagamet, in a deal that will create the No. 2 pharmaceutical company after Merck. American Home Products, the maker of Advil and Anacin, is acquiring A.H. Robins. Merck, meanwhile, is scarcely standing still. In March the company formed a joint venture with Johnson & Johnson, its New Jersey neighbor, under which Merck will develop over-the-counter versions of patented medicines that Johnson & Johnson...
...have already gone so far as to say in effect that democracy and glasnost are very nearly a disaster. The fact that people . . . no longer want to remain silent and insist on making demands is viewed as taking perestroika too far. I for one, comrades, see this as a success of perestroika...